Phase 1Completed

Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects

Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects

Sponsor
Asceneuron S.A. (Industry)
Enrollment
50 enrolled
Conditions
Drug Drug Interaction
Interventions
Fluvoxamine; Itraconazole; Paroxetine; ASN51
Ages
adults
Registry
NCT06232109

Full record on ClinicalTrials.gov

From the registry

The drug-drug interaction study has been designed to investigate the effect of Fluvoxamine, Itraconazole and Paroxetine on the pharmacokinetics of ASN51

Primary outcomes

  • Cmax of ASN51
  • Tmax of ASN51
  • AUC0-tau of ASN51
  • AUC0-inf of ASN51

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered